83 PHASE ANGLE AND LONG-TERM OUTCOME 5 operating characteristic (ROC) curve analysis was used to identify an optimal cut-off value for PhA as a predictor of mortality. All variables with a p-value < 0.25 in the univariate analysis were included. A two-sided p-value of < 0.05 was considered statistically significant. Statistical analyses were performed using The Statistical Package for the Social Sciences 24.0 (IBM, New York, NY, USA). 5.3 RESULTS Of the 1413 patients admitted during the study period, we included a total of 1023 patients in our analysis. A total of 390 patients were not included due to exclusion criteria (132) or absence of BIA measurements (258). At admission, patients were 68 (60-74) years old, 67% was male, and BMI was 26.3 (23.9-29.4) Table 1. Baseline and 1-year survival All Survivors Non-survivors p-value Number of patients, n 1023 908 115 Sex, male, n (%) 686 (67) 609 (67) 77 (67) .980 Age, years 68 [60-74] 67 [60-74] 70 [63-75] .091 BMI, kg/m2 26 [24-29] 26 [24-29] 27 [24-29] .504 Admission type, n (%) Elective Acute 648 (63) 374 (37) 615 (68) 292 (32) 33 (29) 82 (71) < .001 Sepsis, n (%) 79 (8) 56 (6) 23 (20) < .001 Malignancy, n (%) 130 (13) 97 (11) 33 (29) < .001 Mechanical ventilation, n (%) 853 (83) 758 (84) 95 (83) .793 Laboratory tests, CRP, mg/l Creatinine, µmol/l Albumin, g/l 16 [4-100] 85 [70-104] 26 [21-31] 13 [3-81] 84 [69-101] 27 [21-32] 49 [6-153] 106 [72-153] 24 [19-29] .002 < .001 .004 APACHE III 57 [47-71] 55 [46-67] 86 [65-119] < .001 Resistance, Ω Reactance, Ω Phase Angle, ˚ Phase Angle < 4.6, n (%) 449 [385-508] 42 [42-51] 5.4 [4.6-6.4] 268 (26) 449 [388-508] 43 [37-51] 5.4 [4.7-6.4] 211(23) 444 [360-519] 38 [28-48] 4.7 [3.9-6.0] 57 (49) .521 < .001 < .001 < .001 Abbreviations: BMI, Body Mass Index; CRP, C-reactive protein; APACHE, Acute Physiology and Chronic Health Evaluation; BIA, Bio Impedance Analysis. Results are displayed as: number (percentage) or as median [interquartile range]. P-value represent difference between survivors compared with non-survivors
RkJQdWJsaXNoZXIy MjY0ODMw